Evidence map›Paper›PMID 34230221›Full record

ArticleAging2021

LncRNA HCG11/miR-579-3p/MDM2 axis modulates malignant biological properties in pancreatic carcinoma via Notch/Hes1 signaling pathway.

Jin Xu, Weixue Xu, Xuan Yang, Zhen Liu, Qinyun Sun

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jin XuDepartment of Pancreatic and Thyroid Surgery, Shengjing Hospital, China Medical University, Shenyang, China.
Weixue XuDepartment of Pancreatic and Thyroid Surgery, Shengjing Hospital, China Medical University, Shenyang, China.
Xuan YangDepartment of Pancreatic and Thyroid Surgery, Shengjing Hospital, China Medical University, Shenyang, China.
Zhen LiuDepartment of Pancreatic and Thyroid Surgery, Shengjing Hospital, China Medical University, Shenyang, China.
Qinyun SunDepartment of Pancreatic and Thyroid Surgery, Shengjing Hospital, China Medical University, Shenyang, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncreasing reports have revealed that dysregulated expression of long non-coding RNAs (lncRNAs) is involved in pancreatic carcinoma progression. This study intends to explore the function and molecular mechanism of lncRNA HLA complex group 11 (HCG11) in pancreatic carcinoma.

methodsThe expression profiles of HCG11 in pancreatic carcinoma samples were detected by qPCR. Bioinformatics analysis was applied to detect the associations among HCG11/miR-579-3p/MDM2. The malignant properties of pancreatic carcinoma cells were measured by numerous biological assays. Xenograft model was exploited to detect the effect of HCG11 on tumor growth.

resultsA significant increase of HCG11 was occurred in pancreatic carcinoma samples. Knockdown of HCG11 suppressed the progression of pancreatic carcinoma cells. Bioinformatics analysis revealed that HCG11 upregulated MDM2 expression by competitively targeting miR-579-3p. The rescue assays showed that miR-579-3p reversed cell behaviors caused by HCG11, and MDM2 reversed cell properties induced by miR-579-3p. The Notch1 intracellular domain (NICD) and Hes1 protein levels were increased by overexpression of HCG11/MDM2. The tumor growth was suppressed after depletion of HCG11, followed by suppressing Ki67, PCNA and Vimentin expression, increasing TUNEL-positive cells and E-cadherin expression.

conclusionsOur observations highlighted that HCG11 contributed to the progression of pancreatic carcinoma by promoting growth and aggressiveness, and inhibiting apoptosis via miR-579-3p/MDM2/Notch/Hes1 axis.

Indexed as

Signal TransductionAnimalsApoptosisBase SequenceCell Line, TumorCell MovementCell ProliferationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiceMicroRNAsPancreatic NeoplasmsProto-Oncogene Proteins c-mdm2Receptors, NotchReproducibility of ResultsHES1 protein, humanlong noncoding RNA HCG11, humanMDM2 protein, humanMicroRNAsMIRN579 microRNA, humanProto-Oncogene Proteins c-mdm2Receptors, NotchRNA, Long NoncodingTranscription Factor HES-1ceRNAlncRNA HCG11malignant behaviorsNotch/Hes1pancreatic carcinoma

Identifiers

PMID34230221
PMCPMC8266358
OpenAlexW3174545305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.